Yoshida K, Maaieh M M, Shipley J B, Doloresco M, Bernardo N L, Qian Y Z, Elliott G T, Kukreja R C
Division of Cardiology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.
Mol Cell Biochem. 1996 Jun 7;159(1):73-80. doi: 10.1007/BF00226065.
The purpose of this study was to evaluate the protective effect of a new endotoxin analogue, monophosphoryl lipid A (MLA) in a rabbit model of myocardial ischemia/reperfusion and to show if this protection was mediated via synthesis of 70 kDa heat shock protein (HSP 70). Three groups of New Zealand White rabbits underwent 30 min coronary occlusion, followed by 4 hours reperfusion. First group of rabbits (n = 6) were treated with 0.35 ml vehicle (40% propylene glycol, 10% ethanol in water). The second and third group of rabbits (n = 6-8) were treated with MLA (35 micrograms/kg, i.v.) 12 and 24 hours prior to ischemia and reperfusion. MLA treatment either 12 or 24 h prior to ischemia/reperfusion demonstrated significantly reduced infarct size (12.5 +/- 1.7 and 14.7 +/- 2.1% for 12 and 24 h) when compared with vehicle control (40.4 +/- 8.6%, mean +/- S.E.M, p < 0.05). No significant differences in the infarct size was observed between the 12 and 24 h MLA treated groups. The area at risk was not significantly different between the three groups. Baseline values of heart rate, systolic and diastolic blood pressure were not significantly different between the control and MLA treated groups. However, the systolic as well as diastolic blood pressure during reperfusion were significantly lower in rabbits treated with MLA. Western blot analysis of the protein extracts of the hearts (n = 2/group) demonstrated no increase in the expression of the inducible form of HSP 70 following treatment with MLA. We conclude that MLA has significant anti-infarct effect in rabbit which is not mediated by the cardioprotective protein HSP 70. The anti-infarct effect of this drug is superior to the reported protective effects of delayed ischemic or heat stress preconditioning. We hypothesize that the pharmacologic preconditioning afforded by MLA is accomplished via a unique pathway that bypasses the usual intracellular signaling pathways which lead to the myocardial protection with the expression of heat shock proteins.
本研究的目的是评估新型内毒素类似物单磷酰脂质A(MLA)在兔心肌缺血/再灌注模型中的保护作用,并探究这种保护作用是否通过70 kDa热休克蛋白(HSP 70)的合成介导。三组新西兰白兔经历30分钟冠状动脉闭塞,随后进行4小时再灌注。第一组兔子(n = 6)用0.35 ml赋形剂(40%丙二醇,10%乙醇水溶液)治疗。第二组和第三组兔子(n = 6 - 8)在缺血和再灌注前12小时和24小时用MLA(35微克/千克,静脉注射)治疗。与赋形剂对照组(40.4 +/- 8.6%,平均值 +/- 标准误,p < 0.05)相比,缺血/再灌注前12小时或24小时给予MLA治疗均显著减小梗死面积(12小时为12.5 +/- 1.7%,24小时为14.7 +/- 2.1%)。12小时和24小时MLA治疗组之间梗死面积无显著差异。三组之间的危险区域无显著差异。对照组和MLA治疗组之间心率、收缩压和舒张压的基线值无显著差异。然而,MLA治疗的兔子在再灌注期间的收缩压和舒张压均显著降低。对心脏蛋白质提取物(每组n = 2)进行的蛋白质印迹分析表明,MLA治疗后诱导型HSP 70的表达没有增加。我们得出结论,MLA在兔中有显著的抗梗死作用,且这种作用不是由心脏保护蛋白HSP 70介导的。该药物的抗梗死作用优于报道的延迟缺血或热应激预处理的保护作用。我们推测,MLA提供的药物预处理是通过一条独特的途径实现的,该途径绕过了通常导致热休克蛋白表达从而实现心肌保护的细胞内信号通路。